Newer drugs are more targeted than standard agents, but their incorporation into treatment regimens is challenging because of the risk of cardiovascular and infectious adverse events.
Multidisciplinary collaboration coupled with the use of multimodal strategies has enabled the tailoring of treatment plans based on the patient’s medical status and type of surgery.
The updated formulations more closely target the XBB lineage of the Omicron variant, and it is anticipated that they will better fight currently circulating variants.
Awareness of a patient’s potential procedures and changes in nutritional intake enables the pharmacist to prevent hypoglycemic events by proactively adjusting the insulin regimen.